NCT04754750View on ClinicalTrials.gov

Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Schizophrenics
Interventions
DRUG

Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]

DRUG

Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]

All Listed Sponsors
lead

Calo Psychiatric Center

OTHER

NCT04754750 - Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment | Biotech Hunter | Biotech Hunter